What is the recommended approach to evaluating and managing peripheral arterial disease?

Approach to Peripheral Vascular Disease

Begin with ankle-brachial index (ABI) measurement in all patients with suspected PAD, then initiate comprehensive medical therapy—including antiplatelet therapy, high-intensity statin, blood pressure control, smoking cessation, and supervised exercise training for at least 3 months—before considering any revascularization. 1, 2

Initial Diagnostic Evaluation

Measure resting ABI in both legs to confirm PAD diagnosis in patients with exertional leg symptoms, nonhealing wounds, age ≥65 years, or age ≥50 years with smoking or diabetes history. 1 An ABI ≤0.90 confirms PAD; an ABI >1.40 indicates noncompressible vessels (common in diabetes and renal disease) and requires toe-brachial index measurement instead. 3

Perform a comprehensive vascular assessment that includes:

• Detailed symptom review for walking impairment, claudication distance, rest pain, and nonhealing wounds 1, 2, 3
• Complete lower-extremity pulse examination with direct foot inspection (shoes and socks removed) 1, 3
• Blood pressure measurement in both arms to detect subclavian stenosis (difference >15-20 mmHg) 3
• Complete blood count, chemistries (glucose, renal function), electrocardiogram 1

Use duplex ultrasound to diagnose anatomic location and degree of stenosis when revascularization is being considered. 1

Comprehensive Medical Therapy (First-Line for All PAD Patients)

Antiplatelet Therapy

Prescribe clopidogrel 75 mg once daily as the preferred antiplatelet agent to reduce myocardial infarction, stroke, and vascular death in all symptomatic PAD patients. 1, 2 Aspirin 75-325 mg daily is an acceptable alternative only when clopidogrel cannot be used. 1, 2

In high-risk PAD patients without high bleeding risk, add rivaroxaban 2.5 mg twice daily to aspirin 100 mg daily to further reduce cardiovascular and limb events, especially after lower-extremity revascularization. 2, 3

Do not use dual antiplatelet therapy (aspirin + clopidogrel) routinely in stable PAD—it increases major bleeding without additional cardiovascular benefit. 2 Do not add warfarin to antiplatelet therapy unless a specific indication exists (e.g., atrial fibrillation)—it offers no benefit and markedly increases bleeding risk. 2

Lipid Management

Initiate high-intensity statin therapy immediately upon PAD diagnosis, targeting LDL-C <55 mg/dL with ≥50% reduction from baseline. 2 If target is unmet on maximally tolerated statin, add ezetimibe; if still above target, add a PCSK9 inhibitor (evolocumab or alirocumab). 2 For statin-intolerant patients, use bempedoic acid alone or combined with a PCSK9 inhibitor. 2

Blood Pressure Control

Target systolic blood pressure 120-129 mmHg if tolerated, or <140/90 mmHg in patients ≥85 years, with severe frailty, or symptomatic orthostatic hypotension. 2 Use ACE inhibitors or ARBs as first-line agents because they reduce cardiovascular events and may improve walking distance. 2 Beta-blockers are safe and effective in PAD—they do not worsen claudication and should not be withheld. 2

Smoking Cessation

At every encounter, ask about tobacco use, provide counseling, and develop a quit plan with pharmacotherapy (varenicline, bupropion, or nicotine-replacement therapy unless contraindicated). 2

Diabetes Management

Target HbA1c <7% to reduce microvascular complications. 2 Implement daily foot-care measures: appropriate footwear, podiatric review, daily inspection, skin hygiene, and prompt treatment of lesions. 2

Supervised Exercise Training (Mandatory Before Revascularization)

Supervised exercise training (SET) is the initial treatment for intermittent claudication and must be attempted before any revascularization—it carries Class I, Level A evidence. 1, 2

Prescribe SET with the following parameters:

• Frequency: ≥3 sessions per week 2
• Duration: 30-60 minutes per session 2
• Program length: minimum 12 weeks 2
• Intensity: high-intensity (77-95% of maximal heart rate or Borg 14-17) 2
• Modality: walking as first-line activity 2
• Pain level: exercise to moderate-severe claudication pain to maximize distance gains 2

When SET is unavailable, offer structured home-based exercise training (HBET) with remote monitoring (telephone, logbooks, or connected devices), although it is inferior to supervised programs. 2

Continue SET after endovascular revascularization as adjunctive therapy to preserve functional improvements. 2

Pharmacologic Therapy for Claudication

Prescribe cilostazol 100 mg twice daily for all patients with lifestyle-limiting claudication to improve symptoms and walking distance. 1, 2 Cilostazol is contraindicated in patients with heart failure. 2

Pentoxifylline 400 mg three times daily may be used as a second-line alternative, although its clinical benefit is marginal. 2

Indications for Revascularization (Only After 3-Month Trial of Medical Therapy)

Revascularization should be considered only after a 3-month trial of optimal medical therapy and supervised exercise in patients with persistent lifestyle-limiting symptoms and impaired quality of life. 1, 2

All of the following mandatory criteria must be met before proceeding:

1. Completion of supervised exercise and pharmacotherapy with inadequate symptomatic response 1, 2
2. Significant disability affecting work or important daily activities 1, 2
3. Ongoing comprehensive risk-factor modification and antiplatelet therapy 1, 2
4. Lesion anatomy presenting low procedural risk and high probability of immediate and long-term technical success 1, 2

After the 3-month period, reassess PAD-related quality of life; revascularization may be pursued if quality of life remains impaired. 2

For femoro-popliteal lesions, drug-eluting endovascular therapy is the preferred first-line strategy; open surgical bypass using autologous vein should be considered in low-risk patients when a suitable vein is available. 2

Revascularization is NOT recommended solely to prevent progression to critical limb-threatening ischemia (CLTI) and is NOT indicated in asymptomatic PAD. 2, 3

Evidence Supporting Medical-First Approach

The CLEVER trial demonstrated that supervised exercise training produced superior treadmill walking performance at 6 months compared with primary stenting for aorto-iliac PAD. 2 A Dutch retrospective cohort of 54,504 patients showed that revascularization was associated with higher rates of secondary procedures and increased 5-year mortality versus SET alone. 2

Critical Limb-Threatening Ischemia (CLTI) – Medical Emergency

Early recognition of CLTI and immediate referral to a vascular team are essential for limb salvage. 1, 2, 3 CLTI is defined by ischemic rest pain, ulceration, or gangrene; untreated, it leads to major limb amputation within 6 months. 1

Patients with CLTI require:

• Expedited evaluation of amputation-risk factors (diabetes, neuropathy, chronic renal failure, infection) 1, 2
• Prompt revascularization to restore pulsatile flow to at least one foot artery 2
• Immediate systemic antibiotics for ulceration or infection 1, 2
• Referral to specialized wound-care providers 1
• Off-loading of mechanical tissue stress for CLTI-related ulcers 2

Patients at risk for CLTI (ABI <0.4 with diabetes or any diabetic with known PAD) should undergo regular foot inspection. 1, 2 An absolute systolic blood pressure ≤50 mmHg at the ankle or ≤30 mmHg at the toe often implies that amputation may be required without successful revascularization. 1

Patients with diabetes, neuropathy, chronic renal failure, or infection who develop acute limb symptoms represent vascular emergencies and should be assessed immediately by a vascular specialist. 1

Acute Limb Ischemia – Vascular Emergency

In patients with acute limb ischemia and a salvageable extremity, perform emergent evaluation that defines the anatomic level of occlusion and leads to prompt endovascular or surgical revascularization. 1

If the limb is non-viable, do not perform vascular anatomy evaluation or revascularization attempts. 1

Follow-Up and Surveillance

All PAD patients should have at least annual follow-up to assess clinical status, medication adherence, limb symptoms, and cardiovascular risk factors; duplex ultrasound is performed as needed. 2, 3

Patients with prior CLTI or successful CLTI treatment should be evaluated at least twice yearly by a vascular specialist due to high recurrence risk. 1, 2, 3, 4

Long-term patency of infrainguinal bypass grafts should be monitored through a surveillance program that includes vascular history, resting ABI, physical examination, and periodic duplex ultrasound at 3,6, and 12 months, then yearly. 1, 2

Patients at risk for or treated for CLTI should receive verbal and written instructions for self-surveillance of recurrence. 1, 2

Common Pitfalls to Avoid

Do not proceed directly to revascularization without first completing a 3-month trial of optimal medical therapy and supervised exercise in patients with intermittent claudication. 2

Do not add warfarin to antiplatelet therapy without a clear indication—it increases bleeding risk without cardiovascular benefit. 2

Do not prescribe cilostazol to patients with heart failure—it is contraindicated. 2

Do not delay referral to a vascular team in patients with CLTI—early recognition and treatment are critical for limb salvage. 2, 4

Do not assume absence of pain means absence of severe disease in diabetic patients—neuropathy can mask ischemic pain. 4 Approximately 40% of PAD patients have no leg symptoms, so management decisions should be based on objective testing rather than symptoms alone. 4